Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Cogstate Ltd ( (AU:CGS) ) is now available.
Cogstate Limited announced a change in the interests of its director, Bradley O’Connor, specifically regarding an increase in performance rights. The director’s performance rights increased by 591,822, valued at approximately $1,047,525.94, as approved by shareholders at the recent AGM. This change reflects the company’s ongoing commitment to aligning executive incentives with shareholder interests, potentially impacting the company’s strategic direction and stakeholder confidence.
The most recent analyst rating on (AU:CGS) stock is a Buy with a A$3.00 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.
More about Cogstate Ltd
Cogstate Limited operates in the healthcare industry, focusing on cognitive science and technology solutions. The company provides products and services that support clinical trials, brain health assessments, and cognitive research, with a market focus on enhancing brain health and facilitating drug development.
YTD Price Performance: 166.21%
Average Trading Volume: 233,351
Technical Sentiment Signal: Buy
Current Market Cap: A$472M
See more insights into CGS stock on TipRanks’ Stock Analysis page.